Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostatin with camrelizumab and chemotherapy as first-line treatment for driver gene-negative advanced non-small cell lung cancer
ChiCTR2100049033Phase 4Not yet recruiting
- Sponsor
- Department of Respiration, the Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of camrelizumab and endostar in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Department of Respiration, the Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: progression-free survival. Planned start Mar 2021; status: not yet recruiting.
02
Drugs
camrelizumabendostar
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100049033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049033.